Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer a Single-arm, Multicenter Prospective Phase II Study
Latest Information Update: 07 Sep 2022
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Paclitaxel (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 06 Oct 2020 New trial record